Retraction: Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation (PLoS ONE (2011) 6: 10 (e26003) DOI: 10.1371/journal.pone.0026003);Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Hu, Jie ^a   Wang, Zheng ^a   Fan, Jia ^a   Dai, Zhi ^a   He, Yi Feng ^a   Qiu, Shuang Jian ^a   Huang, Xiao Wu ^a   Sun, Jian ^a   Xiao, Yong Sheng ^a   Song, Kang ^a   Shi, Ying Hong ^a   Sun, Qi Man ^a   Yang, Xin Rong ^a   Shi, Guo Ming ^a   Yu, Lei ^a   Yang, Guo Huan ^a   Ding, Zhen Bin ^a   Gao, Qiang ^a   Tang, Zhao You ^a   Zhou, Jian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENETIC VARIABILITY; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MICROARRAY ANALYSIS; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY; BLOOD; DNA MICROARRAY; GENETICS; GENOTYPING TECHNIQUE; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; REPRODUCIBILITY; VIROLOGY;

HEPATITIS B VIRUS;

CARCINOMA, HEPATOCELLULAR; DNA; FEMALE; GENETIC VARIATION; GENOTYPING TECHNIQUES; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECURRENCE; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 80053582122     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0222258     Document Type: Erratum

References (58)

1. El-Serag HB, (2007) Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 37 (Suppl 2): S88-94.
2. Kudo M, (2008) Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 75 (Suppl 1): 1-12.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, (2011) Global Cancer Statistics. CA Cancer J Clin 61: 69-90.
4. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. (2006) Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 243: 229-235.
5. Poon RT, Fan ST, Tsang FH, Wong J, (2002) Locoregional therapies for hepatocellular carcinoma: A critical review from the surgeon's perspective. Ann Surg 235: 466-486.
6. Fabris C, Toniutto P, Falleti E, Fontanini E, Cussigh A, Bitetto D, et al. (2009) MTHFR C677T polymorphism and risk of HCC in patients with liver cirrhosis: role of male gender and alcohol consumption. Alcohol Clin Exp Res 33: 102-107.
7. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423.
8. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, et al. (2010) New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 16: 4688-4694.
9. Lux H, Flammann H, Hafner M, Lux A, (2010) Genetic and molecular analyses of PEG10 reveal new aspects of genomic organization, transcription and translation. PLoS One 5 (1): e8686.
10. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, et al. (1998) Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 280: 1077-1082.
11. Minmin S, Xiaoqian X, Hao C, Baiyong S, Xiaxing D, et al. (2011) Single Nucleotide Polymorphisms of Toll-Like Receptor 4 Decrease the Risk of Development of Hepatocellular Carcinoma. PLoS ONE 6 (4): e19466.
12. Qiu P, Wang L, Kostich M, Ding W, Simon JS, Greene JR, (2004) Genome wide in silico SNP-tumor association analysis. BMC Cancer 4: 4.
13. Sidransky D, (2002) Emerging molecular markers of cancer. Nat Rev Cancer 2: 210-219.
14. Goebel G, Zitt M, Zitt M, Müller HM, (2005) Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 21: 105-120.
15. Fleischhacker M, Schmidt B, (2007) Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775: 181-232.
16. Fleischhacker M, Schmidt B, (2008) Cell-free DNA resuscitated for tumor testing. Nat Med 14: 914-915.
17. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985-990.
18. Anker P, Mulcahy H, Stroun M, (2003) Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer 103: 149-152.
19. Fan J, Yang GS, Fu ZR, Peng ZH, Xia Q, Peng CH, et al. (2009) Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 135: 1403-1412.
20. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM, (2010) Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 51: 1237-1243.
21. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, et al. (2008) Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 40: 3548-3553.
22. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184.
23. Tuefferd M, De Bondt A, Van Den Wyngaert I, Talloen W, Verbeke T, Carvalho B, et al. (2008) Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arrays. Genes Chromosomes Cancer 47: 957-964.
24. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. (1996) Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. N Engl J Med 334: 693-699.
25. Washburn K, Edwards E, Harper A, Freeman R, (2010) Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 10: 1643-1648.
26. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. (2001) Liver transplantation for HCC: expansion of the tumor size limits does not adversely impact survival. Hepatology 33: 1394-1403.
27. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10: 35-43.
28. Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, et al. (2008) Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers. J Hepatol 49: 581-588.
29. Hernandez-Vargas H, Lambert M-P, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, et al. (2010) Hepatocellular Carcinoma Displays Distinct DNA Methylation Signatures with Potential as Clinical Predictors. PLoS ONE 5 (3): e9749.
30. Lu B, Ma Y, Wu G, Guo H, Liang A, Cong W, et al. (2008) Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma. Clin Cancer Res 14: 7405-7412.
31. Deng YB, Nagae G, Midorikawa Y, Yagi K, Tsutsumi S, Yamamoto S, et al. (2010) Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 101: 1501-1510.
32. Mizuguchi Y, Mishima T, Yokomuro S, Arima Y, Kawahigashi Y, et al. (2011) Sequencing and Bioinformatics-Based Analyses of the microRNA Transcriptome in Hepatitis B-Related Hepatocellular Carcinoma. PLoS ONE 6 (1): e15304.
33. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, et al. (2011) MicroRNA Profile Predicts Recurrence after Resection in Patients with Hepatocellular Carcinoma within the Milan Criteria. PLoS ONE 6 (1): e16435.
34. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004.
35. Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, et al. (2010) Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology 51: 1255-1263.
36. Li Y, Zhu Z, Zhang S, Yu D, Yu H, et al. (2011) ShRNA-Targeted Centromere Protein A Inhibits Hepatocellular Carcinoma Growth. PLoS ONE 6 (3): e17794.
37. Niu D, Feng H, Chen WN, (2010) Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery. J Proteomics 73: 1283-1290.
38. Wu L-M, Yang Z, Zhou L, Zhang F, Xie H-Y, et al. (2010) Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma. PLoS ONE 5 (12): e14460.
39. Bai DS, Dai Z, Zhou J, Liu YK, Qiu SJ, Tan CJ, et al. (2009) Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology 49: 460-470.
40. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Peñas R, et al. (2005) 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 23: 9105-9112.
41. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380.
42. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P, et al. (2001) About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313: 139-142.
43. Ren N, Qin LX, Tu H, Liu YK, Zhang BH, Tang ZY, et al. (2006) The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132: 399-407.
44. Bucasas KL, Pandya GA, Pradhan S, Fleischmann RD, Peterson SN, Belmont JW, (2009) Assessing the utility of whole-genome amplified serum DNA for array-based high throughput genotyping. BMC Genet 10: 85.
45. Feo F, De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Frau M, et al. (2006) Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta 1765: 126-147.
46. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531.
47. Kim BK, Park JY, Kim do Y, Kim JK, Kim KS, Choi JS, et al. (2008) Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver International 28: 393-401.
48. Kim CM, Koike K, Saito I, Miyamura T, Jay G, (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351: 317-320.
49. Paterlini P, Poussin K, Kew M, Franco D, Brechot C, (1995) Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 21: 313-321.
50. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, et al. (2009) Significance of Des-Gamma-Carboxy Prothrombin in Selection Criteria for Living Donor Liver Transplantation for Hepatocellular Carcinoma. Am J Transplant 9: 2362-2371.
51. Harper A, O'Mahony CA, Sebastian A, Cheng S, Klintmalm G, O'Mahony CA, et al. (2010) An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant 10: 2092-2098.
52. Schwartz M, Roayaie S, Konstadoulakis M, (2007) Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4: 424-432.
53. Li C, Liu Q, Li N, Chen W, Wang L, Wang Y, et al. (2008) EAPF/Phafin-2, a novel endoplasmic reticulum-associated protein, facilitates TNF-alpha-triggered cellular apoptosis through endoplasmic reticulum-mitochondrial apoptotic pathway. J Mol Med 86: 471-484.
54. Mizutani Y, Kihara A, Igarashi Y, (2006) LASS3 (longevity assurance homologue 3) is a mainly testis-specific (dihydro) ceramide synthase with relatively broad substrate specificity. Biochem J 398: 531-538.
55. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, et al. (2009) MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15: 9-20.
56. Sugimoto N, Imoto I, Fukuda Y, Kurihara N, Kuroda S, Tanigami A, et al. (2001) IQGAP1, a negative regulator of cell-cell adhesion, is upregulated by gene amplification at 15q26 in gastric cancer cell lines HSC39 and 40A. J Hum Genet 46: 21-25.
57. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, et al. (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70: 512-519.
58. Páez G, Richard S, Bianchi MS, Bianchi NO, (2001) Loss of heterozygosity (LOH) in 15q26.2->ter in breast cancer. Mutat Res 484: 103-106.